To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Methcathinone(2-(methylamino)-propiophenone, α-methylamino-propiophenone) is a psychoactive stimulant. It is sometimes used as a recreational drug and is considered to be addictive. It is usually snorted, but can be smoked, injected, or taken orally. Methcathinone is currently a DEA Schedule I controlled substance in the United States.
The C=O bond at the Rβ-position (directly right of the benzene ring) is slightly polar, and as a result the drug does not cross the lipid blood-brain barrier quite as well as amphetamine. Nevertheless, it is a potent CNS stimulant and dopamine reuptake inhibitor. Chronic high dosage use may result in acute mental confusion ranging from mild paranoia to psychosis. These symptoms typically disappear quickly if use is stopped.
Unlike methamphetamine, methcathinone is not legal under any circumstances due to its classification as a Schedule I substance. In contrast, methamphetamine has certain medical uses such as treatment of morbid obesity, narcolepsy, and ADHD.
Methcathinone was first synthesized in Germany in 1928. It was used in the Soviet Union during the 1930s and 1940s as an anti-depressant. Since the 1960s, methcathinone has been used as a recreational drug in the (former) Soviet Union.
Methcathinone is very similar in structure to ethcathinone, rare cathinone analogue and cathinone, a stimulant alkaloid occurring in the shrub Catha edulis (Khat), the synthetic stimulant methamphetamine, and other phenethylamines.
Methcathinone has a single chiral carbon atom, thus yielding enantiomeric + and - forms.
Methcathinone is most commonly made by the oxidation of ephedrine. Oxidation of ephedrine to methcathinone requires little chemistry experience, making it easy to synthesize. Potassium permanganate (KMnO4) is most commonly used as the oxidant.
Synthesizing methcathinone using either potassium permanganate or various chromates is considered undesirable because of the low yields and the high toxicity of these oxidants. A method that yields more methcathinone is oxidizing ephedrine with sodium hypochlorite. If done in a proper laboratory using the proper procedures, however, potassium permanganate can be a high-yielding reactant.
Methcathinone as free base is very unstable; it easily loses its ketone status and converts back into an alcohol. Structurally, this occurs when the C=O bond at the Rβ-position is converted into a C-OH bond. In other words, basic methcathinone will turn into ephedrine, from which it was synthesized.
Methcathinone acts on the body and brain much like methamphetamine and amphetamines do.
Methcathinone hydrochloride increases spontaneous rodent locomotor activity, potentiates the release of dopamine from dopaminergic nerve terminals in the brain, and causes appetite suppression. Users can easily forget to consume fluids and a state of thirst and dehydration is apparent.
The effects of methcathinone are similar to those of methamphetamine, initially deemed to be less intense by the inexperienced user, and often more euphoric. The effects have been compared to those of cocaine, since it commonly causes hypertension (elevated blood pressure) and tachycardia (elevated heart rate). Reported effects include:
The effects of methcathinone usually last from four to six hours.
Use and pharmacology
Methcathinone has very strong affinities for the dopamine transporter and the noradrenaline transporter. Its affinity for the serotonin transporter is less than that of methamphetamine.
Anecdotal reports have provided some information on patterns of methcathinone use. The most common route of administration is via nasal insufflation (snorting). Other routes of administration include oral ingestion, intravenous injection and smoking.
Methcathinone binges resemble amphetamine binges in that the user may not sleep or eat, and takes in little in the way of liquids. The methcathinone binge is followed by a "crash" characterized by long periods of sleep, excess eating and, in some cases, depression.
Use of this substance has recently been associated with symptoms similar to those seen in patients with Parkinson's Disease (Manganism) due to the compound Manganese Dioxide which is a byproduct of synthesis with Permanganate.
Street slang for methcathinone may include terms such as Cat, Jeff, Bathtub Speed, Wannabe-Speed, Kitty, Meth's Cat, or Meth's Kitten.
In Europe, methcathinone is primarily known as Ephedrone.
In Australia, methcathinone may be known as Goey, Speed, Gas, Go, Wiz, Wizzo, Rev, Tweak (primarily distributed in a gel-like form measured in "points," or 1/10ths of a gram), Red Meth, Ketone Stuff.
In South Africa it is primarily known as CAT or occasionally KAT. There, it is also confused (via name alone, not presentation) with Khat (sometimes spelled Qat). Another confusing name is that given to Tik - the local name for methamphetamine.
In preclinical studies, methcathinone hydrochloride produces an abuse potential similar to that of the amphetamines.
Methcathinone can be highly psychologically addictive, and can produce methamphetamine-like withdrawals, which is somewhat less in intensity than methamphetamine. It is highly unlikely for a methcathinone user to experience addiction on their first or even several subsequent administrations of the drug.
In drug discrimination studies, methcathinone hydrochloride evokes responses similar to those induced by both (+)-amphetamine sulphate and cocaine hydrochloride. When examined in particular pharmacological assays for psychomotor stimulant-like activity, both the d and l enantiomeric forms of methcathinone hydrochloride have been found to be pharmacologically active. In these assays, the l-form of methcathinone is more active than either d-methcathinone or (+)-amphetamine. Racemic methcathinone hydrochloride is intravenously self-administered by baboons, thus indicating that methcathinone produces reinforcing effects in this laboratory animal, and suggesting that the drug has a potential for abuse in the human population.
As a Schedule-1 drug, there is no legal clinical use. Research without a specific DEA permit is prohibited.
Furthermore, anecdotal reports from USENET posts in the 1990s indicate that unlike many stimulants, Methcathinone probably doesn't have the inhibitory effects (mediated by norepinephrine) seen in other stimulants that make them useful as medications to treat Attention Deficit Hyperactivity Disorder.
Other related phenethylamine drugs and plants:
Other CNS-active phenyl-ethylamino ketones (Drugs that contain the cathinone core structure):
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Methcathinone". A list of authors is available in Wikipedia.|